Limited distribution could be a path to approval sooner, rather than later, for Vivus' obesity drug Qnexa following the Endocrinologic and Metabolic Drugs Advisory Committee's recommendation against approval July 15
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.
The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.
In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.
